Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
|Date:||Presentation to be accessible on-demand, beginning
|Format:||Virtual company presentation and 1-on-1 meetings|
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
+44 (0) 207 495 2379
+1 646 970 4681
Source: Tiziana Life Sciences Ltd.